BACKGROUND _ AIMS: @entity1744 ( @entity2195 ) is the most @entity740 , with few treatment options. @entity2195 affects 10%-20% of the population; as many as 58% of @entity1 have @entity1142 -predominant @entity2195 ( @entity2195 ). We evaluated efficacy and safety of a standardized, specifically formulated @entity1058 ( @entity1058 ) preparation in treatment of @entity1 with @entity2195 . METHODS: We performed a double-blind trial of 125 @entity1 with @entity2195 (according to @entity3354 ), who were recruited from 13 medical centers or clinics in Australia from July 2009 through February 2012. @entity1 were randomly assigned to groups given a standardized extract of 7  selected @entity1058 ingredients (n  = 61) or placebo (controls, n  = 64) for 8 weeks (5 capsules, twice daily). Subjects were then followed for 16 weeks. Chemical definition, standardization, and stability testing of the formulation were completed. Subjects completed a self-administered, validated binary questionnaire of global symptom improvement at weeks 2, 4, 8, and 16 (primary outcome). Secondary outcomes included results from the self-administered @entity2195 Symptom Severity Scale and the Bristol Stool Form Scale (BSFS), which were completed at weeks 4, 8, and  16. RESULTS: There was statistically and clinically significant (per protocol analyses) improvement among subjects who received @entity1058 (n  = 50) vs controls (n  = 58) for 8 weeks. A greater proportion of subjects receiving @entity1058 reported adequate relief (P  = .010). Compared with controls, the @entity1058 group had improved bowel habits vs controls at week 8, including lower @entity2195 Symptom Severity Scale scores (P < .001), reduced straining during defecation (P  = .002), and a significant decrease in hard lumpy stools (P  = .031). The @entity1058 group also had increased stool consistency, which was based on the Bristol Stool Form Scale (week 8, P < .001). There was no statistically significant difference between groups in @entity490 at week 8 (P  = .692). The @entity1058 was well-tolerated. CONCLUSIONS: In a prospective, controlled study, @entity1058 reduced symptoms of @entity2195 , increased bowel satisfaction and stool consistency, and reduced straining and hard lumpy stools, compared with placebo. Clinical trial registration no: ACTRN12609000558224.

Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of XXXX : A Randomized Controlled Trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity3354 :: ('MESH:C565336', 'Disease') :: ['Rome III criteria'] @entity740 :: ('MESH:D051436', 'Disease') :: ['common chronic functional bowel disorder'] @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain'] @entity1058 :: ('MESH:C562377', 'Disease') :: ['CHM', 'Chinese herbal medicine'] @entity2195 :: ('OMIM:211750', 'Disease') :: ['IBS-C', 'IBS'] @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation'] @entity1744 :: ('MESH:D043183', 'Disease') :: ['Irritable bowel syndrome']
@entity1744 :: (MESH:D043183,Disease) :: ['Constipation-predominant Irritable Bowel Syndrome']
